280110-69-2Relevant articles and documents
Development of autotaxin inhibitors: A series of tetrazole cinnamides
Thomson, Christopher G.,Le Grand, Darren,Dowling, Mark,Beattie, David,Elphick, Lucy,Faller, Michael,Freeman, Mark,Hardaker, Elizabeth,Head, Victoria,Hemmig, Rene,Hill, Johan,Lister, Andrew,Pascoe, David,Rieffel, Sebastien,Shrestha, Binesh,Steward, Oliver,Zink, Florence
, (2020/11/20)
A series of inhibitors of Autotaxin (ATX) have been developed from a high throughput screening hit, 1a, which shows an alternative binding mode to known catalytic site inhibitors. Selectivity over the hERG channel and microsomal clearance were dependent on the lipophilicity of the compounds, and this was optimised by reduction of clogD whilst maintaining high affinity ATX inhibition. Compound 15a shows good oral exposure, and concentration dependent inhibition of formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic (PK/PD) experiments.
AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE
-
, (2015/02/02)
The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS
-
Page/Page column 46-47, (2010/11/24)
Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents a group selected from H, CF3, and C1-6 alkyl (optionally substituted by C1-6 alkyloxy or triazolyl); R2/